A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies

被引：0

作者：

Sen, S. ^{[1
]}

Spira, A. I. ^{[2
]}

Sommerhalder, D. ^{[3
]}

Meric-Bernstam, F. ^{[4
]}

Subbiah, V. ^{[4
]}

Berlin, J. D. ^{[5
]}

Parikh, A. ^{[6
]}

Cecchini, M. ^{[7
]}

Sanborn, R. E. ^{[8
]}

Chablani, P. V. ^{[9
]}

Peoples, G. E. ^{[10
]}

Schurpf, T. ^{[11
]}

Dillon, L. A. ^{[12
]}

Clifton, G. T. ^{[13
]}

Eder, J. P. ^{[14
]}

Tolcher, A. W. ^{[15
]}

机构：

[1] NEXT Oncol TM, Phase 1 Trial Ctr, San Antonio, TX USA

[2] Virginia Canc Specialist, Res Inst, Fairfax, VA USA

[3] NEXT Oncol TM, Oncol, San Antonio, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Dept, Houston, TX USA

[5] Vanderbilt Univ, Dept Med, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA

[6] MGH Massachusetts Gen Hosp, Dept Gastrointestinal Oncol, Boston, MA USA

[7] Yale Univ, Yale Canc Ctr, Oncol, Sch Med, New Haven, CT USA

[8] Earle A Chiles Res Inst, Robert Franz Canc Ctr, Med Oncol, Portland, OR USA

[9] UPMC Hillman Canc Ctr, Med Oncol, Pittsburgh, PA USA

[10] Lumabridge LLC, Dept Surg, San Antonio, TX USA

[11] Parthenon Therapeut, Prot Sci, Cambridge, MA USA

[12] Parthenon Therapeut, Translat Med, Cambridge, MA USA

[13] Parthenon Therapeut, Clin Sci, Boston, MA USA

[14] Parthenon Therapeut, Clin Dev, Boston, MA USA

[15] NEXT Oncol TM, Clin Res Director, San Antonio, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2976

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1079TiP

引用

页码：S649 / S650

页数：2

共 50 条

[41] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
Bauer, Todd
Cho, Byong Chul
Heist, Rebecca
Bazhenova, Lyudmila
Werner, Theresa
Goel, Sanjay
Kim, Dong-Wan
Adkins, Douglas
Carvajal, Richard D.
Alva, Ajjai
Eaton, Keith
Wang, Judy
Liu, Yong
Yan, Xiaohong
Christensen, Jamie
Neuteboom, Saskia
Chao, Richard
Pant, Shubham
INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 990 - 1000
[42] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
Powderly, John
Norman, Teleen
Duncan, Meghan
Huber, Martin
O'Neil, Jennifer
Patel, Ekta
Vandross, Andrae
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
[43] First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
Todd Bauer
Byong Chul Cho
Rebecca Heist
Lyudmila Bazhenova
Theresa Werner
Sanjay Goel
Dong-Wan Kim
Douglas Adkins
Richard D. Carvajal
Ajjai Alva
Keith Eaton
Judy Wang
Yong Liu
Xiaohong Yan
Jamie Christensen
Saskia Neuteboom
Richard Chao
Shubham Pant
Investigational New Drugs, 2022, 40 : 990 - 1000
[44] A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors: Dose escalation study
Taylor, Matthew H.
Patel, Manish R.
Powderly, John D.
Woodard, Paul
Chung, Luke
Tian, Hongyu
Hong, Xiang
Hong, Kyu
Valencia, Donna
Huang, Tao
Schebye, Xiao Min
Liao, Charlene
Naing, Aung
CANCER RESEARCH, 2023, 83 (08)
[45] First-in-human study of ZGGS18, a dual specific antibody targeting VEGF and TGF-β, as monotherapy in patients with advanced solid tumors
Zhao, Chuan Hua
Shi, Jianhua
Chai, Xiaoli
Tan, Lirong
Wu, Lihua
Zheng, Li
Cao, Dan
Mai, Gang
Fan, Lianlian
Mi, Yanjun
Wang, Jufeng
Han, Xinghua
Xu, Jianming
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.
Xu, Jian-Ming
Jia, Ru
Wang, Yan
Liu, Rongrui
Zhao, Chuanhua
Zhou, Hui
Xu, Linxinyu
Kong, Xuan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[47] BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in-human phase I study in patients with advanced solid malignancies
Chen, Hua-Jun
Wang, Sheng
Su, Rong
Li, Xu-Feng
Tang, En-Tzu
Wang, Yi-Wei
Hei, Yong-Jiang
Wu, Yi-Long
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors
Voskoboynik, Mark
Liu, Jia
Song, Ki-Hoon
Park, Dong-Guk
Ryu, Min-Hee
Chon, Hong Jae
Kim, Chan
CANCER RESEARCH, 2024, 84 (07)
[49] A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Teixeira, Luis
Medioni, Jacques
Garibal, Julie
Adotevi, Olivier
Doucet, Ludovic
Durey, Marie-Agnes Dragon
Ghrieb, Zineb
Kiladjian, Jean-Jacques
Brizard, Mara
Laheurte, Caroline
Wehbe, Maria
Pliquet, Elodie
Escande, Marie
Defrance, Remy
Culine, Stephane
Oudard, Stephane
Wain-Hobson, Simon
Doppler, Valerie
Huet, Thierry
Langlade-Demoyen, Pierre
CLINICAL CANCER RESEARCH, 2020, 26 (03) : 588 - 597
[50] Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
Hidenori Mizugaki
Noboru Yamamoto
Haruyasu Murakami
Hirotsugu Kenmotsu
Yutaka Fujiwara
Yoshimasa Ishida
Tomohisa Kawakami
Toshiaki Takahashi
Investigational New Drugs, 2016, 34 : 596 - 603

← 1 2 3 4 5 →